Heather McKenzie

Heather McKenzie

Senior Editor

Heather McKenzie is a professional journalist with more than five years experience in the biopharmaceutical industry. Since joining BioSpace, she has written more than 200 features and breaking news articles with a particular focus in neuroscience and gene therapy. She has also traveled internationally to cover global biotech hubs such as Israel. In previous roles, she has covered current affairs, sports, education and politics. She previously spent eight years as a senior content producer for executive-level business conferences in the pharma/biotech, legal, energy and business strategy sectors. In her free time, Heather enjoys creative writing, spending time with family and playing with her energetic Russian Blue cat Roofus. She hails from Toronto and has also lived in Chicago and Chesapeake, Virginia. You can reach her at heather.mckenzie@biospace.com.

The precision medicine company is developing mutant selective and isoform-specific drugs in non-conventional ways for well-known targets in the oncology and autoimmune spaces.
Tonix expects to begin enrollment in the trial for TNX-1900, an intranasal potentiated oxytocin, during the second half of 2022.
FDA
The U.S. Food and Drug Administration approved COVID-19 vaccine booster shots for all Americans ages 18 and over Friday morning.
A week after announcing its intention to spin off its consumer health division, J&J revealed ambitious plans for its pharmaceutical business.
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
This week, Berkshire announced that it has scaled back those investments, and completely eliminated its stake in Merck.
Chroma Medicine debuted Wednesday morning with $125 million in seed and Series A funding.
Respiratory Syncytial Virus has been around for a very long period now. But there was no vaccine yet. But, here’s the first vaccine for RSV to shape the future.
Los Angeles-based ACELYRIN, Inc. announced a quarter-million dollars in Series B financing Tuesday morning, along with a splashy licensing deal.
This year’s top 30 large and small companies operate in some of the Life Sciences’ hottest spaces – precision medicine, vaccines, gene editing, genomics and oncology.
President Joe Biden has nominated former U.S. Food and Drug Administration Commissioner Robert Califf to reprise his role at the agency’s helm.
AC Immune’s Phase II Lauriet study of investigational anti-Tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD), only met one endpoint.
The Oklahoma Supreme Court has overturned the landmark $465 million opioid verdict handed down against Johnson & Johnson in 2019.
The study was momentous in that it was the first head-to-head comparison of two modalities. The Aimovig showed significantly good results and aced primary endpoints.
Alltrna, based in Cambridge, Mass. near its cousin Moderna, debuts as the first platform transfer RNA (tRNA) company.